Raquel Aloyz

The role of DNA repair in nitrogen mustard drug resistance.

Homologous recombinational repair vis-à-vis chlorambucil resistance in chronic lymphocytic leukemia.

DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program.

Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD.

Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.

Chlorambucil cytotoxicity in malignant B lymphocytes is synergistically increased by 2-(morpholin-4-yl)-benzo[h]chomen-4-one (NU7026)-mediated inhibition of DNA double-strand break repair via inhibition of DNA-dependent protein kinase.

XRCC3 depletion induces spontaneous DNA breaks and p53-dependent cell death.

Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.

Therapeutic implications of Src independent calcium mobilization in diffuse large B-cell lymphoma.

Vav-1 expression correlates with NFκB activation and CD40-mediated cell death in diffuse large B-cell lymphoma cell lines.

p53 and autophagy contribute to dasatinib resistance in primary CLL lymphocytes.

A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond.

Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition.

PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes.

Metabolic rewiring beyond Warburg in chronic lymphocytic leukemia: How much do we actually know?

Bruton's tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes.

Using Two Peptide Isotopologues as Internal Standards for the Streamlined Quantification of Low-Abundance Proteins by Immuno-MRM and Immuno-MALDI.

EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.

PARP Inhibition Sensitizes Breast Cancer Cells to Eribulin.

Translational control of leukemic metabolism and disease progression.